A Phase I/IIa, Multicenter, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics of ICP-192 in Patients With Advanced Solid Malignancies

Beijing InnoCare Pharma Tech Co., Ltd.7 sites in 1 country56 target enrollmentDecember 19, 2018

ConditionsSolid Tumor

InterventionsICP-192

Overview

Phase: Phase 1
Intervention: ICP-192
Conditions: Solid Tumor
Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.
Enrollment: 56
Locations: 7
Primary Endpoint: Adverse events(Phase 1 dose escalation)
Status: Recruiting
Last Updated: 3 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

Open-label, non-randomized, Phase I/IIa, dose-escalating, dose-extension, first-in-man study.

Detailed Description

The study consisted of a screening period, a treatment period with 21 days of repeated treatment per cycle (duration treatment with ICP-192), and a follow-up period (28 days after last dose). The recruited patients receive a single dose on day 1, then after a 3-day washout period, repeated dosing will be followed. The starting dose is 2 mg, QD, and dose escalation will follow accelerated titration and modified 3+3 dose-finding schema. The dose-limiting toxicity (DLT) assessment period consisted of Cycle 0 (single dose and washout period) and Cycle 1 (21-day cycle).

Registry

clinicaltrials.gov

Start Date

December 19, 2018

End Date

December 31, 2024

Last Updated

3 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Beijing InnoCare Pharma Tech Co., Ltd.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•An unresectable or metastatic advanced malignant solid tumor confirmed by histopathology that has failed to respond to known treatment or has recurred;Subjects who progress under standard treatment, are intolerant to standard treatment, or do not have standard treatment (dose escalation phase)
•Tissue or cell pathology confirmed unresectable, recurrent or metastatic (AJCC version 8 TNM staging IV (2017), biliary tract malignant tumor, or intolerance to first-line chemotherapy failure (twice (defined as reduction still cannot tolerate) first-line chemotherapy, neoadjuvant/progress/adjuvant chemotherapy after 6 months recurrence can be selected (dose extension stage); - At least one evaluable disease according to RECIST1.1
•FGFR2 translocation/fusion has been reported or FGFR2 translocation/fusion has been detected in central laboratory (dose extension phase);
•Age ≥18 and ≤75
•There is at least one evaluable lesion according to RECIST1.1 criteria
•ECOG strength score is 0-1 (dose escalation stage), and ECOG strength score is 0-2 (dose expansion stage).
•The expected survival time is more than 3 months
•The organ function level must meet the following requirements (subject to the upper limit of normal value in the clinical trial center):
•A) bone marrow: absolute count of neutrophils (ANC)≥1.5\*109/L (1500/mm3), platelet ≥75\*109/L, hemoglobin ≥9g/dL; B) coagulation function: international standardized ratio of prothrombin time and partial thrombin time \<1.5 times the upper limit of normal value; C) liver: serum bilirubin ≤1.5 times the upper limit of normal value (tumor involvement in the liver ≤2.5 times the upper limit of normal value), aspartic aminotransferase (AST) and alanine aminotransferase (ALT)≤3 times the upper limit of normal value (AST and ALT≤5 times the upper limit of normal value in the case of liver metastasis); D) serum creatinine ≤1.5 times the upper limit of normal value, or creatinine clearance ≥70mL/min (calculated according to the Cockroft-gult formula).
•Volunteer to enroll and sign informed consent to follow the treatment protocol and visit plan.

Exclusion Criteria

•Previous treatment with FGFR small molecule inhibitors or antibody drugs.
•Anti-cancer therapy, such as chemotherapy (except for oral fluorouracil), immunotherapy, hormonal, targeted therapy, or investigational agents within four weeks of the first dose of ICP-192, oral fluorouracil agents within two weeks of the first dose of ICP-
•Major surgery within 6 weeks of the first dose of ICP-
•Blood phosphate persistently above ULN with intervene therapy within two weeks of the first dose of ICP-
•Significant GI disorder(s) that could interfere with the absorption, metabolism, or excretion of ICP-
•Central nervous system (CNS) metastasis
•Current clinically significant cardiovascular disease including:
•Any class 3 or 4 cardiac disease such as arrhythmia, congestive heart failure or myocardial infarction defined by the New York Heart Association Functional Classification, or left ventricular ejection fraction (LVEF) \< 50%, Primary cardiomyopathy, clinical significant QTc prolong history or QTc\>470ms (female) QTc\>450ms (male)
•Known active bleeding within 2 months of screening or 6 months of bleeding history.
•According to the investigator's judgement, there are evidences of a serious or uncontrollable systemic disease (such as unstable or uncompensated respiratory, liver or kidney disease); or any unstable systemic disease (including active clinically serious infections, uncontrolled hypertension, liver and kidney or metabolic diseases)

Arms & Interventions

ICP-192

The initial dose of ICP-192 is 2 mg, QD, and dose escalation schedule may be modified based on the safety and PK from the previous dose. Tentatively seven dose levels will be evaluated.

Intervention: ICP-192

Outcomes

Primary Outcomes

Adverse events(Phase 1 dose escalation)

Time Frame: From the time a signed and dated ICF until 28 days after last dose of study drug

Adverse events graded by CTCAE V5.0 as a measurement of the safety and tolerability profile of ICP-192

Objective Response Rate(ORR)(Phase 2a dose expansion)

Time Frame: At the end of Cycle 4(each cycle is 21 days)

Objective response based on assessment of confirmed Complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST).

Secondary Outcomes

Cmax(At the end of Cycle 1(each cycle is 21 days))
Food effect(Day 1 - 6 after single dose)
Objective Response Rate(ORR) (Phase 1 dose escalation)(At the end of Cycle 4(each cycle is 21 days))
AUC(At the end of Cycle 1(each cycle is 21 days))
Apparent half-life for designated elimination phases (t½)(At the end of Cycle 1(each cycle is 21 days))
Disease control rate(DCR)(At the end of Cycle 4(each cycle is 21 days))
Duration of Objective Response (DOR)(At the end of Cycle 4(each cycle is 21 days))
Progression Free Survival (PFS)(At the end of Cycle 4(each cycle is 21 days))
Correlationship between FGFR aberrations with efficacy. (Phase 2a dose expansion)(At the end of Cycle 4(each cycle is 21 days))